Clinical Cancer Research prints topic-specific mini collections that showcase a handful of our recent publications. In this installment, we highlight papers that review molecular pathways of interest and discuss their clinical-translational potential, with a focus on drug development, clinical testing, and strategies on how the field should move forward. We hope you enjoy this complimentary CCR collection.
- Mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy.
Kohlhapp FJ and Kaufman HL. Clinical Cancer Research March 1, 2016.
- Isocitrate dehydrogenase mutations in cancer.
Clark O…Mellinghoff IK. Clinical Cancer Research April 15, 2016.
- AXL, a membrane receptor mediator of resistance to therapy.
Scaltriti M…Baselga J. Clinical Cancer Research March 15, 2016.
- Mitochondrial reprogramming in tumor progression and therapy.
Caino MC…Altieri DC. Clinical Cancer Research February 1, 2016.
- Targeting cancer stem cells awakened by chemotherapy to abrogate tumor repopulation.
Chan KS. Clinical Cancer Research February 15, 2016.
- Immune checkpoint antibodies and their toxicities.
Cousin S and Italiano A. Clinical Cancer Research September 15, 2016.
Clinical Cancer Research Editorial Office
American Association for Cancer Research | Publications Division
615 Chestnut Street | 17th Floor | Philadelphia, PA 19106-4404
Phone: (215) 440-9300 | Fax: (215) 440-9354 | E-mail: email@example.com